Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D01CGV
|
||||
Former ID |
DIB016697
|
||||
Drug Name |
LY-2599506
|
||||
Synonyms |
PSN-010
|
||||
Indication | Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] | Phase 2 | [522877] | ||
Company |
Prosidion Ltd
|
||||
Structure |
Download2D MOL |
||||
Target and Pathway | |||||
Target(s) | Glucokinase | Target Info | Inhibitor | [551195] | |
KEGG Pathway | Glycolysis / Gluconeogenesis | ||||
Galactose metabolism | |||||
Starch and sucrose metabolism | |||||
Amino sugar and nucleotide sugar metabolism | |||||
Butirosin and neomycin biosynthesis | |||||
Metabolic pathways | |||||
Biosynthesis of antibiotics | |||||
Carbon metabolism | |||||
Insulin signaling pathway | |||||
Insulin secretion | |||||
Prolactin signaling pathway | |||||
Glucagon signaling pathway | |||||
Type II diabetes mellitus | |||||
Maturity onset diabetes of the young | |||||
Central carbon metabolism in cancer | |||||
Pathway Interaction Database | FOXA2 and FOXA3 transcription factor networks | ||||
HIF-1-alpha transcription factor network | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.